YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
YD Bio Limited announced that its U.S. clinical laboratory affiliate, EG BioMed US Inc., has obtained clinical lab licenses in Rhode Island and Pennsylvania, expanding its U.S. lab footprint to 46 states plus DC and Guam. This expansion enhances patient access to early cancer detection tests based on DNA methylation and supports the company's trans…